History

MorphoSys was founded in Martinsried near Munich in 1992. The founders included Dr. Simon Moroney, today’s CEO of the Company and Prof. Dr. Andreas Plückthun. Today, MorphoSys is one of the world’s leading biotechnology companies in the area of fully human antibodies.

 

Year

 

 

 

 

Event

 

 

1992

 

 

Company founded in Martinsried/Munich, Germany

 

 

1997

 

 

First commercial partnership with Pharmacia-Upjohn

Move to the Innovation and Start-up Center for Biotechnology (IZB) Martinsried

 

 

 

 

1999

 

 

IPO at the Frankfurt Stock Exchange

Start of an extensive partnership with Bayer AG

 

Patent dispute begins with Cambridge Antibody Technology

 

 

 

 

 

2000

 

 

Presentation of the HuCAL antibody library

First HuCAL patent granted

 

 

 

 

2001

 

 

Presentation of the HuCAL GOLD antibody library

Start of a strategic partnership with Schering AG

 

 

 

 

2002

 

 

MorphoSys achieves a settlement of the CAT patent dispute

Dr. Simon E. Moroney receives the Bundesverdienstkreuz am Bande (Cross of the Order of Merit of the Federal Republic of Germany)

 

 

 

 

2003

 

 

Start of a partnership with Pfizer

HuCAL antibodies to combat Alzheimer’s produce positive preclinical results

 

 

 

 

2004

 

 

Start of a strategic partnership with Novartis

Presentation of the new research antibodies division, Antibodies by Design

 

Inclusion in the technology index TecDAX

 

MorphoSys achieves break even

 

 

 

 

 

 

2005

 

 

The first HuCAL antibodies used in clinics

Acquisition of Biogenesis Group strengthens the research segment

 

First partnership with a Japanese pharmaceutical group

 

 

 

 

 

2006

 

 

Acquisition of Serotec Group further strengthens the research segment

HuCAL antibodies to combat Alzheimer’s disease are used in clinics

 

 

 

 

2007

 

 

MorphoSys announces development of new antibody platform technology

MorphoSys and Novartis forge one of the industry’s largest pharma-biotech R&D collaborations

 

 

 

 

2008

 

 

First proprietary therapeutic antibody MOR103 enters clinical trials

MorphoSys unveils new antibody library, HuCAL PLATINUM

 

First HuCAL antibody enters phase 2 clinical trials

 

 

 

 

 

2009

 

 

MorphoSys signs first infectious disease alliance with Daiichi-Sankyo

 

 

2010

First proprietary therapeutic antibody in a patient setting

First in-licensing of a clinical antibody from Xencor

 

Aquisition of Sloning BioTechnology

 

MorphoSys presents new antibody technology arYla

 

 

 

 

 

 

2011

MOR202 enters clinical development

MorphoSys presents new antibody technology Ylanthia

 

MorphoSys signs first industrial biotechnology alliance with Novozymes

 

 

2012

MorphoSys announces positive clinical data for MOR103 in RA and MOR208 in CLL

With gantenerumab from Roche, the first partnered antibody program reaches late stage development

MorphoSys celebrates its 20th anniversary

MorphoSys signs first Ylanthia-based therapeutic partnership

2013

MorphoSys completes sale of AbD Serotec to Bio-Rad

MorphoSys signs license agreement with GlaxoSmithKline for MOR103 program

MorphoSys signs strategic alliance with Celgene for MOR202 program

MorphoSys collaborator Novartis starts pivotal study with bimagrumab

2014

MorphoSys and Merck Serono enter strategic immuno-oncology collaboration

MorphoSys and Emergent BioSolutions sign license agreement to co-develop and commercialize prostate cancer drug candidate MOR209/ES414

 

Product Pipeline

The pipeline is increasingly taking center stage.